MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells
Kathleen A. Bridges(The University of Texas MD Anderson Cancer Center), Raymond E. Meyn(The University of Texas MD Anderson Cancer Center)
Cited by 37
Related Papers
The MEK/ERK Pathway Acts Upstream of NFκB1 (p50) Homodimer Activity and Bcl-2 Expression in a Murine B-Cell Lymphoma Cell Line
|Journal of Biological Chemistry|2003|69